Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines for papillomavirus infection.

Ian Frazer1

  • 1Centre for Immunology and Cancer Research, The University of Queensland, Princess Alexandra Hospital, Ipswich Road, 4102, Brisbane, Australia. ifrazer@medicine.pa.uq.edu.au

Virus Research
|November 26, 2002
PubMed
Summary

Preventive vaccines using Papillomavirus (PV) virus-like particles (VLPs) show promise for preventing cervical cancer. Further research is needed for therapeutic vaccines and standardized markers to assess efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating 12 Spatial and Single Cell Technologies to Characterise Tumour Neighbourhoods and Cellular Interactions in three Skin Cancer Types.

bioRxiv : the preprint server for biology·2025
Same author

A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma.

Frontiers in oncology·2024
Same author

Salivary micro RNAs as biomarkers for oropharyngeal cancer.

Cancer medicine·2023
Same author

Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages.

Cancers·2022
Same author

The Innovation: A Journal to See the Unseen and Change the Unchanged.

Innovation (Cambridge (Mass.))·2021
Same author

Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers.

Science translational medicine·2021

Area of Science:

  • Virology
  • Immunology
  • Oncology

Background:

  • Human Papillomavirus (HPV) infection is a major cause of cervical cancer.
  • Preventive vaccines utilizing HPV L1 virus-like particles (VLPs) are in clinical trials and demonstrate high potential for success.
  • Therapeutic vaccines targeting existing HPV infections are in early developmental stages.

Purpose of the Study:

  • To evaluate the potential of VLP-based vaccines for preventing HPV infection and cervical cancer.
  • To highlight the need for surrogate markers to compare the efficacy of different therapeutic HPV vaccine strategies.

Main Methods:

  • Clinical trials of HPV L1 VLP vaccines.
  • Review of early-stage therapeutic HPV vaccine development.
  • Discussion on the requirement for validated surrogate markers for therapeutic vaccine assessment.

Main Results:

  • Preventive HPV VLP vaccines exhibit characteristics suggesting successful deployment within a decade.
  • Therapeutic HPV vaccine development requires further advancement and standardized evaluation methods.
  • Reduction in viral load is proposed as a key surrogate marker for therapeutic vaccine efficacy.

Conclusions:

  • Global planning for HPV VLP vaccine deployment is warranted to prevent cervical cancer.
  • Development of effective therapeutic HPV vaccines necessitates further research and validated surrogate markers.
  • Standardized markers are crucial for comparing diverse therapeutic vaccine approaches.

Related Experiment Videos